Abbott Laboratories (NYSE:ABT) received FDA approval to launch the Liberta RC DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people ...
(RTTNews) - Abbott (ABT) announced the FDA has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation system in treatment-resistant depression. Abbott's DBS ...
Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system System offers the longest ...
Abbott Laboratories received U.S. FDA approval for its Liberta RC deep brain stimulation (DBS) system for use in movement disorders, less than two weeks after the agency gave its nod to Medtronic’s ...
The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this ...
Credit: Abbott. Liberta RC DBS is the smallest rechargeable DBS device featuring the NeuroSphere Virtual Clinical, which allows for remote programming capabilities. The Food and Drug Administration ...
Abbott Laboratories is launching a clinical trial applying its deep brain stimulation system to a tough-to-treat form of depression. The company called its "Transcend" study a pivotal trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results